Breast Cancer Clinical Trial
A Study of BMS-986249 Alone and in Combination With Nivolumab in Advanced Solid Tumors
Summary
The purpose of this study is to determine whether BMS-986249 both by itself and in combination with Nivolumab is safe and tolerable in the treatment of advanced solid tumors
Eligibility Criteria
Inclusion Criteria:
Histologic or cytologic confirmation of a solid tumor that is advanced (metastatic, recurrent, and/or unresectable) with measurable disease or metastatic disease documented by either bone lesions on radionuclide bone scan and/or soft tissue lesions on CT/MRI for prostate cancer and have at least 1 lesion accessible for biopsy. For Part 2B participants with HCC, intermediate disease is allowed.
Eastern Cooperative Oncology Group Performance Status of 0 or 1
Must have received, and then progressed, relapsed, or been intolerant to, at least 1 standard treatment regimen in the advanced or metastatic setting according to tumor type, if such a therapy exists
Prior anti-cancer treatments such as chemotherapy, radiotherapy, or hormonal are permitted for some participants
Willing and able to comply with all study procedures
Exclusion Criteria:
Primary central nervous system (CNS) malignancies, tumors with CNS metastases as the only site of disease or active brain metastases will be excluded
Other active malignancy requiring concurrent intervention
Prior organ allograft
Active, known, or suspected autoimmune disease
Other protocol-defined inclusion/exclusion criteria apply
Check Your Eligibility
Let’s see if you might be eligible for this study.
What is your age and gender ?
There are 44 Locations for this study
Aurora Colorado, 80045, United States
Denver Colorado, 80218, United States
Miami Florida, 33176, United States
Baltimore Maryland, 21287, United States
Hackensack New Jersey, 07601, United States
New York New York, 10032, United States
New York New York, 10065, United States
Cincinnati Ohio, 45219, United States
Eugene Oregon, 97401, United States
Philadelphia Pennsylvania, 19104, United States
Greenville South Carolina, 29605, United States
Austin Texas, 78705, United States
Dallas Texas, 75246, United States
Houston Texas, 77030, United States
San Antonio Texas, 78240, United States
Tyler Texas, 75702, United States
Leesburg Virginia, 20176, United States
Norfolk Virginia, 23502, United States
Vancouver Washington, 98684, United States
Buenos Aires Distrito Federal, 1121, Argentina
Caba Distrito Federal, C1430, Argentina
Buenos Aires , C1426, Argentina
North Sydney New South Wales, 2060, Australia
Adelaide South Australia, 5000, Australia
Frankston Victoria, 3199, Australia
Heidelberg Victoria, 3084, Australia
Edmonton Alberta, T6G 1, Canada
Santiago Metropolitana, 84203, Chile
Helsinki , 00029, Finland
Essen , 45147, Germany
Hamburg , 20251, Germany
Heidelberg , 69120, Germany
Milan , 20133, Italy
Napoli , 80131, Italy
Siena , 53100, Italy
Warszawa , 02-78, Poland
Bucharest , 02232, Romania
Craiova , 20054, Romania
Badalona Barcelona [Barcelona], 08916, Spain
Madrid Madrid, Comunidad De, 28027, Spain
Barcelona , 08035, Spain
Madrid , 28040, Spain
Madrid , 28041, Spain
Malaga , 29010, Spain
How clear is this clinincal trial information?

Please confirm you are a US based health care provider:
Yes, I am a health care Provider No, I am not a health care providerSign Up Now.
Take Control of Your Disease Journey.
Sign up now for expert patient guides, personalized treatment options, and cutting-edge insights that can help you push for the best care plan.